Graig Suvannavejh
Stock Analyst at Mizuho
(4.48)
# 244
Out of 5,182 analysts
178
Total ratings
52.59%
Success rate
19.99%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $41 | $40.39 | +1.51% | 13 | Apr 2, 2026 | |
| IMMX Immix Biopharma | Maintains: Outperform | $14 → $15 | $8.62 | +74.01% | 2 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Outperform | $204 → $206 | $164.86 | +24.95% | 14 | Mar 25, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $120.38 | +107.68% | 2 | Feb 25, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $10.02 | -0.20% | 1 | Feb 19, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $16.60 | -69.88% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $52.79 | +2.29% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $167.25 | +15.99% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $27.96 | +64.52% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $70.22 | +42.41% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $10.01 | +129.77% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $65.40 | -14.37% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $32.48 | +41.63% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $171.78 | +17.59% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.22 | +227.87% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.16 | +18,304.91% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.53 | +38.34% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.09 | +139.23% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.33 | +87.62% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $14.43 | -23.77% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.02 | +99.69% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.35 | -44.25% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $30.31 | +8.87% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.38 | +450.72% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.98 | +641.48% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.96 | -66.22% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $88.12 | -60.28% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $42.81 | -81.31% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $66.61 | -14.43% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $33.58 | -85.11% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.27 | +442.26% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $11.01 | +154.31% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $33.14 | -6.46% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $17.39 | +2,085.16% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.35 | +251.85% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $24.10 | +49.38% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $29.76 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $3.45 | +972.46% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $188.27 | -32.01% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Apr 2, 2026
Maintains: Neutral
Price Target: $20 → $41
Current: $40.39
Upside: +1.51%
Immix Biopharma
Mar 30, 2026
Maintains: Outperform
Price Target: $14 → $15
Current: $8.62
Upside: +74.01%
Insmed
Mar 25, 2026
Maintains: Outperform
Price Target: $204 → $206
Current: $164.86
Upside: +24.95%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $120.38
Upside: +107.68%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $10.02
Upside: -0.20%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $16.60
Upside: -69.88%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $52.79
Upside: +2.29%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $167.25
Upside: +15.99%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $27.96
Upside: +64.52%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $70.22
Upside: +42.41%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.01
Upside: +129.77%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $65.40
Upside: -14.37%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $32.48
Upside: +41.63%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $171.78
Upside: +17.59%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.22
Upside: +227.87%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.16
Upside: +18,304.91%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.53
Upside: +38.34%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.09
Upside: +139.23%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.33
Upside: +87.62%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $14.43
Upside: -23.77%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.02
Upside: +99.69%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.35
Upside: -44.25%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $30.31
Upside: +8.87%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.38
Upside: +450.72%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.98
Upside: +641.48%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.96
Upside: -66.22%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $88.12
Upside: -60.28%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $42.81
Upside: -81.31%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $66.61
Upside: -14.43%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $33.58
Upside: -85.11%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $6.27
Upside: +442.26%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $11.01
Upside: +154.31%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $33.14
Upside: -6.46%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $17.39
Upside: +2,085.16%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.35
Upside: +251.85%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $24.10
Upside: +49.38%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $29.76
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $3.45
Upside: +972.46%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $188.27
Upside: -32.01%